Taysha Gene Therapies, Inc.
NASDAQTaysha Gene Therapies heads into the final weeks before its August earnings date with short sellers trimming exposure and the lending pool remaining comfortably loose — a setup that contrasts with the stock's still-elevated headline short interest figure. The short interest story is one of steady retreat. At 13.1% of the free float, the short position remains meaningfully large…
Snapshot as of 18 Jun 2026
Taysha Gene Therapies heads into the final weeks before its August earnings date with short sellers trimming exposure and the lending pool remaining comfortably loose — a setup that contrasts with the stock's…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TSHA — free to start on ORTEX.
Sign up for free →Open TSHA on ORTEX